Inventiva

Unternehmensprofil

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Beschreibung auf Englisch verfügbar.

Unternehmensdaten

Branche

Gesundheit

Industrie

Biotechnology

Land

Frankreich

Hauptsitz

50 rue de Dijon, 21121, Daix

Mitarbeitende

87

Notierung

IVA · Euronext Paris

Währung

EUR

ISIN

FR0013233012

Website

inventivapharma.com